The 2-drug combinations alpelisib + UC2288 and UC2288 + OHT, the 3-drug combinations alpelisib + UC2288 + OHT and talazoparib + UC2288 + OHT, and the 4-drug combination alpelisib + UC2288 + OHT + talazoparib selectively and synergistically reduced the ATP levels of ERα + breast cancer cell lines, including the tamoxifen-resistant MCF7/LCC2 cells, as compared to ERα-negative and non-cancerous cells (Fig. S8C-H). The gene discussed is ESR1; the disease is breast carcinoma.